Food and Drug Administration (FDA) Regulatory Compliance Training
ID: HT9425-25-R-0050Type: Combined Synopsis/Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)ARMY MED RES ACQ ACTIVITYFORT DETRICK, MD, 21702, USA

NAICS

All Other Professional, Scientific, and Technical Services (541990)

PSC

SUPPORT- PROFESSIONAL: OTHER (R499)

Set Aside

Total Small Business Set-Aside (FAR 19.5) (SBA)
Timeline
  1. 1
    Posted Mar 27, 2025, 12:00 AM UTC
  2. 2
    Updated Apr 10, 2025, 12:00 AM UTC
  3. 3
    Due Apr 18, 2025, 6:00 PM UTC
Description

The Department of Defense, through the Army Medical Research Acquisition Activity, is seeking qualified contractors to provide FDA Regulatory Compliance Training for personnel involved in FDA-regulated research activities. The training will cover essential areas such as Good Clinical Practices (GCP), Good Laboratory Practices (GLP), current Good Manufacturing Practices (cGMP), and Quality Systems Regulations (QSR), ensuring that personnel maintain competency and compliance with U.S. FDA and Department of Defense regulations. This initiative is critical for the U.S. Army Medical Research and Development Command (USAMRDC) as it aims to deliver FDA-approved pharmaceuticals and devices to military personnel, adhering to stringent regulatory standards. Interested parties should contact Matthew Gembe at matthew.w.gembe.civ@health.mil or call 301-619-1350 for further details, with the contract expected to commence in May 2025 and extend through April 2030.

Point(s) of Contact
Files
Title
Posted
Mar 27, 2025, 8:06 PM UTC
The document outlines a Request for Proposals (RFP) for FDA Regulatory Compliance Training under solicitation number HT942525R0050 by the United States Army Medical Research and Development Command (USAMRDC). The training aims to enhance the competency of personnel involved in FDA-regulated research, covering areas like Good Clinical Practices (GCP), Good Laboratory Practices (GLP), current Good Manufacturing Practices (cGMP), and Quality Systems Regulations (QSR). The scope includes developing instructional materials and conducting face-to-face and virtual sessions at Fort Detrick, MD, starting approximately on May 1, 2025, with an emphasis on maintaining compliance with federal regulations. The contractor will provide various training sessions, structured into introductory and refresher levels, and is responsible for materials preparation, attendance tracking, and post-training evaluations. The RFP specifies performance requirements, management responsibilities, and quality assurance processes, ensuring accountability and effective training outcomes. Emphasis is placed on submission deadlines for training materials, monthly reporting, and adherence to security protocols for contractor personnel. Overall, the document reinforces the USAMRDC's commitment to regulatory compliance and personnel training in support of its mission to deliver FDA-approved medical products to military personnel.
Apr 10, 2025, 7:05 PM UTC
The document is a solicitation by the United States Army Medical Research and Development Command (USAMRDC) for FDA Regulatory Compliance Training, specifically targeting training in Good Clinical Practices (GCP), Good Laboratory Practices (GLP), current Good Manufacturing Practices (cGMP), and Quality Systems Regulations (QSR). The training aims to ensure that personnel involved in FDA-regulated activities maintain competency and compliance with pertinent federal and Department of Defense regulations. The contract will span from May 2025 with both face-to-face sessions at Fort Detrick, MD, and virtual training sessions via Microsoft Teams. It outlines the delivery of introductory and refresher courses, along with specific training requirements and performance standards. The performance work statement stipulates a rigorous training framework, including monthly progress reports and the need for comprehensive feedback mechanisms to evaluate the effectiveness of training. Specific deadlines for training material submissions and attendance reporting are also highlighted to ensure compliance and accountability. This initiative reflects the USAMRDC's commitment to providing necessary compliant training while prioritizing the mission of delivering FDA-approved products to military personnel.
Apr 10, 2025, 7:05 PM UTC
The document is a Non-Disclosure Agreement (NDA) from the U.S. Army Medical Research and Development Command (USAMRDC) directed towards contractor employees and subcontractors associated with USAMRDC contracts. The NDA emphasizes the confidential nature of sensitive information that may be accessed while performing tasks related to the contract, including business, technical, financial, and proprietary data. Signatories agree not to disclose such information except to authorized personnel involved in the contract execution. The NDA outlines potential legal consequences for unauthorized disclosure, including court-imposed penalties, and specifies exceptions for information that is public or disclosed with consent. A requirement is also included for individuals to disclose their NDA obligations to future employers. The overall purpose of the document is to protect sensitive government and contractor data, ensuring that any proprietary information remains confidential during and after the term of employment. This agreement's importance is underscored in the context of government RFPs and grants, where safeguarding sensitive information is crucial for maintaining competitive advantage and compliance with federal regulations.
The U.S. Army Medical Research and Development Command (USAMRDC) has established organizational conflict of interest (OCI) guidelines to mitigate competitive disadvantages during contract awards. Service procurements are categorized into three types: Internal Support, Admin/Acquisition Support/IT, and Product Support. The document outlines that involvement in more than one category can create real or perceived OCIs, affecting impartiality and competition fairness. Contractors must certify their OCI status when bidding. If they have not previously supported the USAMRDC in multiple categories, they are eligible to bid without further action. However, those with past multi-category involvement must provide a comparative analysis of potential OCIs and, if necessary, an OCI Avoidance or Mitigation Plan with their proposal. The Contracting Officer will review these submissions to ensure compliance with OCI regulations. The document emphasizes proper disclosure and management of conflicts to protect the integrity of the contracting process, articulating potential sanctions for breaches. By defining these measures, USAMRDC aims to promote fair competition and maximize opportunities for all contractors while adhering to federal regulations under FAR Subpart 9.5.
Apr 10, 2025, 7:05 PM UTC
The document outlines the requirements for providing past performance references in the context of federal RFPs and grants. It includes specific fields to fill out for three separate past performance references, which are essential for evaluating the offeror's previous work relevant to the solicitation. Each reference requires details such as the offeror’s name, the contracting organization, contract numbers, performance issues, and corrective actions taken, alongside contact information for the contracting officer and program manager. The evaluation criteria include a concise description of the requirement, relevance to the current solicitation, and any performance problems that arose, including how they were addressed. The document's structure is designed to gather comprehensive and comparable past performance information to assess offerors’ capabilities and reliability effectively in government contracting contexts. Overall, the emphasis is on ensuring quality and accountability in government procurement processes.
Apr 10, 2025, 7:05 PM UTC
This document outlines a Pricing Sheet and Supplemental Pricing Sheet for Regulatory Compliance Training provided by the Food and Drug Administration (FDA) in support of the Office of Regulatory Affairs (ORA). It includes multiple years of training with specified periods of performance. The training courses mentioned include Introductory and Refresher courses in Good Clinical Practices (GCP), Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), and Quality System Regulations (QSR), spanning from May 2025 to April 2030. Each course is presented in a structured format with Clear Line Item Numbers (CLINS), indicating various training offerings for each period. The total values for all courses for each contract year are listed as zero, suggesting a preliminary or undefined pricing structure. Additionally, the supplemental sheet mentions labor categories for training hours required for each course but lacks specific data on hours or costs. The primary purpose of this document appears to be a response to a government request for proposals (RFP) focusing on compliance training services, emphasizing a systematic approach for planning and budgeting training initiatives across multiple years to ensure effective regulatory adherence within the FDA.
Lifecycle
Title
Type
Combined Synopsis/Solicitation
Similar Opportunities
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Buyer not available
The Department of Defense (DoD) is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement (BPA) and the Uniform Formulary Additional Discount Program (ADP) through the Defense Health Agency (DHA). This procurement aims to establish agreements for pharmaceutical agents that will be included in the DoD's Uniform Formulary, which is essential for providing effective pharmacy benefits to military personnel and their families. The upcoming Pharmacy and Therapeutics (P&T) Committee meeting, scheduled for May 7-8, 2025, will review newly approved drugs, with quotes due by April 17, 2025. Interested manufacturers should contact Keith Marasigan at keith.b.marasigan2.ctr@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil for further details and to ensure compliance with submission requirements.
Facilities Project Management and Quality Assurance Support Logistics (LOG), Walter Reed Army Institute of Research (WRAIR)
Buyer not available
The Department of Defense, through the Defense Health Agency, is seeking proposals from small businesses for Facilities Project Management and Quality Assurance Support Logistics at the Walter Reed Army Institute of Research (WRAIR). The contract aims to provide essential services for overseeing medical research facility operations and maintenance, ensuring compliance with quality standards across facilities ranging from 22,140 to 1,000,000 square feet. This procurement is critical for maintaining operational continuity and supporting military health research initiatives, with a contract period from May 16, 2025, to May 15, 2030, and options for extensions. Interested parties must submit their proposals by April 21, 2025, and direct inquiries to Nathaniel Reus at nathaniel.a.reus.civ@health.mil or 301-619-9209.
Dimethyl Fumarate DR Presolicitation
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
Request for Proposal - Materiel Fielding and Medical Liaison Support Services
Buyer not available
The Department of Defense, specifically the Army's Program Executive Office Soldier (PEO-S), is soliciting proposals for Materiel Fielding and Medical Liaison Support Services under solicitation number W911QY25RA001. The primary objective is to provide comprehensive medical materiel management, logistics support, and technical assistance to enhance Army medical readiness, particularly concerning Soldier Medical Devices (SMD). This procurement is crucial for ensuring that medical equipment and support services are efficiently delivered to military personnel, thereby maintaining operational effectiveness and healthcare standards. Interested small businesses must submit their proposals by April 21, 2025, and can direct inquiries to Patrick Wallace at patrick.j.wallace3.civ@army.mil or Trisha Scott at trisha.r.scott.civ@army.mil.
FDA NCTR On-Site Pathology Services
Buyer not available
The U.S. Food and Drug Administration (FDA) is preparing to solicit comprehensive on-site animal pathology services for its National Center for Toxicological Research (NCTR) to support its research programs aimed at public health protection. The required services will encompass a variety of pathology support tasks, including necropsies, histopathology, and specialized techniques such as immunohistochemistry and respiratory pathology, as dictated by research protocols from Principal Investigators. This opportunity is significant for businesses in the professional, scientific, and technical services sector, with the solicitation number 75F40125R00059 expected to be released around April 30, 2025, and a closing date set for 30 days post-release. Interested parties should monitor SAM.gov for updates and can contact Tim Walbert at timothy.walbert@fda.hhs.gov or 870-543-7267 for further information.
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Buyer not available
The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
Request for Proposals: On-Premises Intellectual Property (IP) and Technology Transfer (T2) Database and Related Services
Buyer not available
The Department of Defense, through the Army Medical Research Acquisition Activity (USAMRAA), is soliciting proposals for an On-Premises Intellectual Property (IP) and Technology Transfer (T2) Database and related services. The procurement aims to acquire a Commercial Patent Docketing and Database Software System to support the United States Army Medical Research and Development Command (USAMRDC) in managing patenting and licensing processes, ensuring compliance with legal requirements, and enhancing data management capabilities. This initiative is critical for effective intellectual property management within the medical research community, with the contract expected to be awarded by May 12, 2025. Interested parties should direct inquiries to Lisa Kuhns at 301-619-2336 or via email at lisa.z.kuhns.civ@health.mil, and proposals must adhere to the specified submission guidelines to be considered.
Request for Information for Structured Product Labeling (SPL) Document Support for DHA R&D - MRDC - ORA
Buyer not available
The Defense Health Agency (DHA) is seeking information through a Request for Information (RFI) regarding Structured Product Labeling (SPL) document support for its Research & Development Medical Research and Development Command (MRDC). The objective is to assess the feasibility of acquiring commercial solutions that facilitate the submission of SPL documents to the FDA for three licensed New Drug Application (NDA) products requiring labeling changes. This initiative is crucial for ensuring compliance with FDA regulations and maintaining the accuracy of product labeling, which is vital for public health and safety. Interested parties must submit their Capabilities Statements by April 17, 2025, detailing their ability to create, update, and submit SPL documents, along with adherence to technical standards and system validation processes. For further inquiries, respondents can contact Alana M. Sowers at alana.m.sowers.civ@health.mil.
Drug Utilization: Hospital Inpatient & Emergency Dept. Data (Recompete)
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking proposals for a contract titled "Drug Utilization: Hospital Inpatient & Emergency Dept. Data (Recompete)." The primary objective of this procurement is to gain immediate and unlimited access to commercially available drug utilization data for both adult and pediatric populations in hospitals, which will support the FDA's regulatory activities related to drug safety and utilization assessments. This data is crucial for enhancing public health safety and informing regulatory decision-making regarding marketed drugs. Interested parties should note that the contract may cover up to $5 million over several years, with a response deadline of April 16, 2025. For further inquiries, potential offerors can contact Ryan Alexander at ryan.alexander@fda.hhs.gov.
Ambr 250 High Throughput Bioreactor System
Buyer not available
The Department of Defense, through the Defense Health Agency, is seeking to procure an Ambr 250 High Throughput Bioreactor System for the Pilot Bioproduction Facility at the Walter Reed Army Institute of Research in Silver Spring, Maryland. This procurement aims to enhance capabilities for monoclonal antibody production, allowing for simultaneous testing of multiple conditions to accelerate the manufacturing of vaccines and biologics for military-relevant infectious diseases. The system must meet specific Minimum Essential Characteristics, including the ability to process up to 12 cultures, automated controls for critical parameters, and compliance with FDA regulations, particularly 21 CFR Part 11 for data integrity. Interested vendors should note that the anticipated solicitation release is on April 10, 2025, with a contract performance period from June 1, 2025, to May 31, 2029. For further inquiries, contact Ms. Brenda Mena at brenda.i.mena.civ@health.mil or Ms. Sharew Hailu at sharew.hailu.civ@health.mil.